![](https://nthumb.tpgimages.com/mid2_com_img/1339/29018/TOP26811726.jpg)
mRNA in lipid nanoparticles, conceptual illustration. Close-up of molecules of mRNA (messenger ribonucleic acid, brown) encapsulated in lipid nanoparticles as utilised in RNA vaccines. These nanoparticles consist of a double membrane containing multiple different types of lipids, such as zwitterionic phospholipids (bottom right), cationic lipids (bottom left), cholesterol (top left), and PEGylated lipids (top right). When injected into humans, the RNA will be taken up and read by the body's cells, causing them to produce copies of viral proteins. The viral proteins will provoke an immune response, priming the body against infection with the actual virus. The first RNA vaccine approved for human use, developed against the SARS-CoV-2 coronavirus by Pfizer/BioNTech, was approved in the UK on 2nd December 2020.
px | px | dpi | = | cm | x | cm | = | MB |
Details
Creative#:
TOP26811726
Source:
達志影像
Authorization Type:
RM
Release Information:
須由TPG 完整授權
Model Release:
N/A
Property Release:
N/A
Right to Privacy:
No
Same folder images: